SEC Pressed Salarius Over Decoy Deal Math, Warrant Terms
Across months of registration-statement review, the SEC pushed Salarius Pharmaceuticals to justify its Decoy Therapeutics valuation, spell out delisting risk and account for warrant liabilities tied to a looming reverse split.
The Securities and Exchange Commission spent months pressing Salarius Pharmaceuticals, Inc. to justify how it valued its own stock in a merger, after staff questioned why the company invoked an "assumed and agreed" value for a public company with a quoted market price. Salarius eventually explained that its $2.1 million market capitalization as of October 2024 anchored a $3.1 million listing valuation, combined with $1.5 million for clinical assets, to reach a $4.6 million figure — while Decoy Therapeutics was pegged at $28 million based partly on a 2022 convertible-note valuation. The company revised its pro forma disclosures to walk through that math after staff flagged inconsistent narrative and quantitative figures across the notes.
The review also forced Salarius to confront its Nasdaq standing directly. Staff pointed to an April 2025 filing showing the company out of compliance with the $1.00 minimum bid price requirement, and to disclosure suggesting the pending financing would itself price below that threshold. Salarius responded that it had appealed a Nasdaq delisting notice and was preparing to present a reverse-split plan to a Nasdaq Hearings Panel, while acknowledging there was no assurance the appeal would succeed or that its shares would stay listed once the financing and merger closed. The company also clarified that it intended to file its Nasdaq initial listing application before the merger closed rather than after, a sequencing point staff had specifically asked it to justify.
That listing mechanics question resurfaced in the most recent letter in the thread, where staff asked Salarius to add a table modeling the effects of a reverse split at three different ratios — 1-for-4, 1-for-20 and 1-for-40 — on authorized shares, shares outstanding and shares available for future issuance. Salarius added the table and confirmed it planned to submit its Nasdaq application under the exchange's equity listing standard. It also clarified how many of Decoy's outstanding convertible notes would exchange into Salarius stock at closing versus remain outstanding afterward.
The most technically consequential exchange concerned the accounting treatment of warrants tied to the financing. Staff asked Salarius to justify its equity classification of common warrants in the pro forma statements, and the company disclosed that the warrants actually fail the indexation test under derivatives accounting rules because of a "Reverse Split Adjustment" provision that resets the exercise price to the lowest five-day volume-weighted average price following a reverse split, floored at 20% of the offering price. Salarius acknowledged the warrants would be liability-classified between the financing's closing and the later conversion of merger-related preferred stock, becoming equity-classified only once that contingency settles — even though the pro forma presentation, which treats both steps as simultaneous, showed them as equity from the start.
Earlier in the dialogue, staff pushed on the science underlying Decoy's pipeline claims, asking Salarius to clarify that antiviral results against measles and Nipah viruses came from computer modeling rather than lab or clinical testing, and to disclose that such results might not replicate in animal or human studies. Salarius added that caveat along with more detail on the modeling itself. Staff also asked the company to disclose grade 4 adverse events that had triggered a clinical hold on one of its own drug candidates, SP-2577, which Salarius added across several sections of the registration statement.
Throughout the exchanges, the SEC repeatedly asked Salarius to reconcile pro forma adjustment figures — including a $6 million financing adjustment net of roughly $1 million in fees, and separate multimillion-dollar adjustments to additional paid-in capital — with the underlying line items on its balance sheet, prompting the company to add tabular breakdowns tying each figure to its components. That granular accounting scrutiny, layered on top of the valuation and warrant questions, shaped a registration statement that grew progressively more explicit about the mechanics and risks of combining a Nasdaq-troubled shell with a private antiviral developer.
By the fifth amendment, Salarius had converted staff's line-by-line accounting and disclosure demands into a materially more detailed public record of how the Decoy merger would be priced, financed and structured — leaving intact, but now fully disclosed, the risk that Nasdaq could still reject the company's bid to stay listed.